MedTrace Logo

Pharmacokinetics, Pharmacodynamics, And Safety Of Maraviroc (UK-427,857) In Patients With Human Immunodeficiency Virus

NCT00643643 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2010-11-10

No results posted yet for this study

Summary

To investigate the relationship between the pharmacokinetics and pharmacodynamics of UK-427,857 and its antiviral effects in patients with human immunodeficiency virus (HIV).

Conditions

  • HIV Infections

Interventions

DRUG

Maraviroc (UK-427,857)

25 mg oral tablet once daily for 10 days

DRUG

Maraviroc (UK-427,857)

50 mg oral tablet twice daily for 10 days

DRUG

Maraviroc (UK-427,857)

100 mg oral tablet twice daily for 10 days

DRUG

Maraviroc (UK-427,857)

300 mg oral tablet twice daily for 10 days

OTHER

Placebo

Matching placebo oral tablet twice daily for 10 days

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • ViiV Healthcare

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-10-31
Primary Completion
2003-06-30
Completion
2003-06-30

Countries

  • Germany
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00643643 on ClinicalTrials.gov